Axsome Therapeutics AXSM Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's operating income?
- Axsome Therapeutics (AXSM) reported operating income of -$63.36M in Q1 2026.
- How has Axsome Therapeutics's operating income changed year-over-year?
- Axsome Therapeutics's operating income decreased by 11.2% year-over-year, from -$56.98M to -$63.36M.
- What is the long-term trend for Axsome Therapeutics's operating income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's operating income has grown at a 7.5% compound annual growth rate (CAGR), from -$124.71M to -$166.76M.
- What does operating income mean?
- Profit earned from core business activities before interest and taxes.
- How do you interpret operating income?
- Positive and growing operating income indicates a self-sustaining and efficient business model.
- How does operating income compare across companies?
- The primary metric for comparing operational performance across the biopharmaceutical industry.